Schneiderman, Jennifer
Qiu, Longhui
Yeap, Xin Yi
Kang, Xin
Zheng, Feibo
Ye, Junsheng
Xie, Yan
Wang, Jiao-Jing
Sambandam, Yuvaraj
Mathew, James
Li, Lin
Leventhal, Joseph
Edelson, Richard L.
Zhang, Zheng Jenny
Article History
Received: 31 December 2021
Accepted: 20 April 2022
First Online: 4 May 2022
Competing interests
: Dr. Schneiderman is a paid scientific consultant for Mallinckrodt; this relationship developed after the work reported in this manuscript was performed and therefore does not pertain to the research. Dr. Edelson, along with other members of his research team, is an inventor of several patents, owned by Yale University, and licensed to the non-commercialized company Transimmune, of which he is a founder. Those proprietary rights do not pertain to the research reported in this manuscript. No other authors report competing interests.